Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCR1 antagonist treatment in patients hospitalized with COVID-19
DRKS00024465Phase 2Terminated
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing BAY86-5277 with Placebo (2 arms). Started Nov 2021; status: terminated.
02
Drugs
BAY86-5277
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on DRKS00024465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00024465.